3 March 2022

Avance Clinical Announces Appointment of Liahna Toy as Head of Business Development

Avance Clinical Announces Appointment of Liahna Toy as Head of Business Development

Sydney, Australia

Avance Clinical, the largest full-service Australian Contract Research Organization (CRO) for international biotechs, announced today the appointment of Liahna Toy to the new senior executive role, Head of Business Development.

Avance Clinical’s CEO Yvonne Lungershausen said: “We are extremely pleased to have Liahna join the team and we know our clients will benefit from her extensive experience and industry knowledge”.

“Avance is continuing to experience significant growth and Liahna is a valuable member of the team to support clients and the team as we expand our services,” she said.

Liahna has more than 11 years of industry experience working across local and global CROs in various proposal management and business development roles focused on attracting EARLY PHASE trials into Australia and the Asia Pacific region.

As the Head of Business Development, Liahna will work closely with Avance Clinical’s business development and leadership teams to establish and maintain client relationships and strategic partnerships, providing clients with optimal solutions to execute their clinical development programs.

Liahna has completed her Master of Business Administration (MBA).

Check for our latest positions open

Avance Clinical recently secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m.

“With the support of Riverside and its powerful global footprint and deep healthcare experience, Avance Clinical will execute on its regional and international expansion plans organically and via acquisitions,” said Lungershausen.

Avance Clinical is the Australian-owned CRO that provides global regulatory standard clinical research services across all phases to the local and international biopharma industry.

The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which has allowed it to expand into clinical trials for vaccines and GMO therapies.

“We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector,” said Lungershausen.

Related Articles